Drug Trial Radar · NCT04972110
Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
156
Actual
Start
Jul 21, 2021
Primary completion
Nov 13, 2024
Study completion Nov 13, 2024
Sponsor
- Lead sponsor
- Repare TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the safety and tolerability of niraparib or olaparib in combination with RP-3500 (camonsertib), in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-3500 (camonsertib) in combination with niraparib or olaparib, examine pharmacokinetics (PK) and assess anti-tumor activity.
Conditions
- Advanced Solid Tumor, Adult
Interventions
RP-3500 (camonsertib)Drug
RP-3500 (camonsertib, ATR inhibitor) in combination with niraparib or olaparib (PARP inhibitors)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the Safety and Tolerability of Niraparib or Olaparib in Combination With RP-3500 in Patients With Molecularly Selected Solid TumorsTime frame: Start of treatment to 30 days post last dose, up to 23.7 months
- Define the Recommended Phase 2 Dose (RP2D) of RP-3500 in Combination With Niraparib or Olaparib in Patients With Molecularly Selected Solid TumorsTime frame: During 21 days (one cycle) from the initiation of the study treatment
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Participating Site #1018
Phoenix, Arizona
Participating Site #1025
San Francisco, California
Participating Site #1028
Aurora, Colorado
Participating Site #1012
New Haven, Connecticut
Participating Site #1017
Jacksonville, Florida
Participating Site #1009
Baltimore, Maryland
Participating Site #1015
Ann Arbor, Michigan
Participating Site # 1016
Rochester, Minnesota
Participating Site #1026
New York, New York
Participating Site # 1008
New York, New York
Participating Site #1029
Eugene, Oregon
Participating Site # 1001
Houston, Texas
Participating Site # 1013
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.